Ge Healthcare Technologies (GEHC) Stock
Global medical technology company for imaging and patient monitoring. Here's the price, business snapshot, and what's worth knowing about Ge Healthcare Technologies in August 2026.
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and services company focused on diagnostic imaging, ultrasound, patient monitoring, life‑sciences tools and bioprocessing, and healthcare IT. With a market capitalisation around $34.7 billion, the business combines capital equipment sales with recurring revenue from service contracts, consumables and software – a mix that can smooth cyclicality in equipment purchases. Key growth drivers include demand for imaging and diagnostics, expansion of bioprocessing for biologics, and adoption of digital and AI tools to improve workflows. Investors should be aware of sensitivity to hospital and clinic capital spending cycles, competitive pressures, reimbursement and regulatory risk, and supply‑chain dynamics. Management execution and capital allocation also matter for returns. This summary is educational only, not personalised advice: values can rise and fall and past performance is not a guide to the future. Check up‑to‑date filings and consult a financial adviser when assessing suitability for your portfolio.
Why It’s Moving
GE HealthCare is drawing attention from a CFO смена, fresh product launches, and mixed headline noise.
- Shares are reacting to GE HealthCare’s CFO transition, with William Grogan set to take over on September 14 after Jay Saccaro stepped down, a move that can trigger short-term attention but also signals continuity in finance leadership.
- Recent product updates, including new LOGIQ e ultrasound systems and an expanded breast-imaging portfolio, are helping reinforce the company’s growth story by showing steady innovation in core imaging categories.
- The stock is also being supported by broader analyst interest and positive sentiment around healthcare technology names, while a separate securities-fraud investigation headline may be adding some noise around the shares.
GE HealthCare is drawing attention from a CFO смена, fresh product launches, and mixed headline noise.
- Shares are reacting to GE HealthCare’s CFO transition, with William Grogan set to take over on September 14 after Jay Saccaro stepped down, a move that can trigger short-term attention but also signals continuity in finance leadership.
- Recent product updates, including new LOGIQ e ultrasound systems and an expanded breast-imaging portfolio, are helping reinforce the company’s growth story by showing steady innovation in core imaging categories.
- The stock is also being supported by broader analyst interest and positive sentiment around healthcare technology names, while a separate securities-fraud investigation headline may be adding some noise around the shares.
Sixth Month Growth Performance
next-earnings-question
GE HealthCare’s next earnings release is typically expected around October 28, 2026, based on the company’s historical reporting pattern. It will cover Q3 2026 results. The exact date has not yet been formally confirmed, so the timing may shift slightly.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GE Healthcare's stock with a target price of $86.35, indicating strong potential.
Financial Health
GE Healthcare is generating strong revenue and cash flow, indicating good financial performance and stability.
Dividend
GE Healthcare's low dividend yield of 0.19% means it offers minimal returns to investors from dividends. If you invested $1000 you would be paid $1.90 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diagnostics and Imaging
Imaging equipment drives sales and higher‑margin service revenue; technological upgrades and AI could support demand, though hospital budgets and reimbursement affect timing.
Life Sciences Growth
Bioprocessing and tools for biologics offer expansion opportunities as biologics production rises, but competition and capital intensity can affect margins.
Global Service Network
Recurring revenue from service contracts and consumables provides stability and customer ties, yet geographic exposure and supply chains can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
